CD274 and endometrial cancer: In addition, an ongoing phase II randomized trial investigating nivolumab monotherapy compared to combination treatment with ipilimumab in advanced endometrial cancer will provide additional evidence for any potential difference in efficacy between combined checkpoint blockade and anti-PD-1/PD-L1 monotherapy (NCT05112601).